Company intelligence / Profile preview

Thrombotech Ltd.

Ownership: Private
Development stage: Phase 2

Overview

Thrombotech developed THR‐18, a synthetic peptide designed to improve the safety and efficacy of tPA-based thrombolytic therapy for ischemic stroke by reducing life-threatening side effects such as brain hemorrhage. The company completed Phase I and initiated multi-center Phase IIa trials in Israel, Europe, India, and received FDA IND approval for U.S. trials around 2012. The trial aimed to demonstrate improved safety when used alongside tPA compared to tPA alone.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Synthetic peptide therapeutics
Industry: Biotech

Drug pipeline

1 asset

THR-18

Phase 2

Indications: Ischemic stroke

Partnerships

Hadasit Bio-Holdings Ltd.Clal Biotechnology Industries Ltd.Ofer Hi-Tech

Beyond the preview

Go deeper on Thrombotech Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thrombotech Ltd..

Explore the full profile